Inactive Instrument

Highlights Taiwan Liposome Company, Ltd. Nasdaq

Equities

TLC

US8740381020

Highlights

Unlock all the news: Be the first to know and act before the market!

Endo Ventures Limited Executes Agreement with Taiwan Liposome Company, Ltd. to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain	22-06-13	CI
TLC BioSciences Announces Publication of Tlc599 Phase Ii Results in Arthritis Research & Therapy	22-03-07	CI
Woods Investment Company, Ltd. completed the acquisition of Taiwan Liposome Company, Ltd. from a group of sellers.	21-10-07	CI
Woods Investment Company, Ltd. agreed to acquire Taiwan Liposome Company, Ltd. from a group of sellers for TWD 9.2 billion.	21-07-04	CI
Taiwan Liposome Company, Ltd. and Endo International plc Enter a Commercialization Agreement for A Liposomal Product	21-07-01	CI
TLC and Strides Pharma Science Limited Partner to Launch Liposomal Amphotericin B in India	21-05-27	CI
Taiwan Liposome : Working With Zydus Healthcare to Provide Supply of AmphoTLC in India	21-05-26	MT
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India	21-05-26	CI
Taiwan Liposome : TLC Secures India's Approval For Mucormycosis Treatment AmphoTLC	21-05-25	MT
Taiwan Liposome : Earnings Flash (TLC) TLC Posts Q1 Loss $-0.08	21-05-14	MT
Taiwan Liposome Company, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Taiwan Liposome Company, Ltd. Provides Clinical Trail Update	21-02-05	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-04	CI
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain	20-12-28	CI
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program	20-11-03	CI
Taiwan Liposome Company, Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI
TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program	20-10-14	CI
TLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19	20-10-06	CI
Taiwan Liposome Company, Ltd. Receives TFDA Acceptance of IND Application of TLC19 for COVID-19	20-10-06	CI
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China	20-08-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Taiwan Liposome Company, Ltd. Nasdaq

Equities

TLC

US8740381020

Highlights

Filters